Strides Fast-Tracks China Entry With JV As It Reports Strong Q1
Executive Summary
Indian firm Strides announces its entry into China through a joint venture with one of the country’s leading pharmaceutical firms, as first-quarter EBITDA soars 155%.
You may also be interested in...
Strides’ Puducherry Plant Gets FDA Warning Letter
India’s Strides has received a warning letter from the US Food and Drug Administration over compliance issues at its Puducherry plant. However, the firm has told investors the regulatory action will not affect its forecast of 20% US sales growth for this financial year.
Bring Them On: China Releases Generics List To Encourage Competition
China's National Health Commission issues list of 34 generic drugs that have 'insufficient' competition, seeking public comments.
Strides' US Revenues Soar, Recovery Strategy ‘Executing To Plan’
Strides Pharma “very confident” about future after Indian generic company’s fourth-quarter US revenues rocketed 181% and EBITDA margins beat market expectations.